Bioengineering & MedTtech against cancer To meet the challenges in healthcare of the 21st century, it is important to combined bioengineering and MedTech to develop biological system analyze and treatment to treat specifically cancer cells and protect the rest of the patient’s body by limiting side effects. To accomplish…
A study led by IBEC researchers from the Nanobioengineering group, uses a functional predictive biomarker to anticipate the effect of treatments against rhabdomyosarcoma, the most common soft-tissue cancer affecting childhood and adolescence.
This advance can help in predicting treatment efficiency thus, avoiding tumor resistance and decreasing undesired secondary effects.
IBEC researchers Elena Martínez, Xavier Trepat and Pere Roca-Cusachs aim to understand the processes that promote metastasis in colorectal cancer using innovative bioengineering tools, such as bioprinting and microscopy capable of revealing forces at the cellular level.
The results will be translated into a device that will recreate the tumor environment from cancer cells derived from patients, as well as a new technology that will allow to visualize how physical forces affect the nuclei of metastatic cells.
The new 3D hydrogels provide high rates of cell proliferation, as they mimic lymph nodes, where T-cells reproduce in vivo. A new project, led by researchers from ICMAB and IBEC, and with the collaboration of VHIO and UIC, wants to transfer this technology to hospitals.
Cancer immunotherapy is based on using and strengthening the patient’s own immune system to recognize and fight tumor cells, without damaging healthy tissues.
IBEC contributes to elucidate how the rigidity of the tumor extracellular matrix affects the aggressiveness of neuroblastoma, a cancerous tumor that affects mainly children. This opens the door to generate more accurate models to predict tumor development in patients and to work in the design of new treatments.
Neuroblastoma is the most frequent malignant tumor in the first year of life. It is caused by a genetic mutation from immature nerve cells (neuroblasts) that the fetus produces as part of its development process.
HealthTECH World Cancer day 2020 HealthTECH World Cancer day 2020 es un evento organizado en el marco del Día Mundial del Cáncer donde se darán a conocer las últimas innovaciones en materia de NANOMEDICINA contra el CÁNCER, con temas que van desde el diagnóstico precoz, la liberación controlada de fármacos…
IBEC-managed Spanish Nanomedicine Platform, NanoMed Spain, is co-hosteing the seventh edition of Health TECH World Cancer Day, a global initiative organized as part of World Cancer Day. It’s the fifth year running that the platform hosts the conference, which will take place next 3rd February at Sala Pau Viladiu at Hospital Duran i Reynals. Josep Samitier (Scientific Coordinator of NANOMED Spain and Director of the Institute for Bioengineering of Catalonia) and Isabel Fabregat (Coordinator of the Molecular Mechanisms and Experimental Therapy in Oncology Program and Researcher at IDIBELL) will be in charge of the opening ceremony.
Samuel Sánchez, Principal Investigator at IBEC talks about microscopic engines carrying antibodies that selectively destroy cancer cells. Specifically in their group, they create urea-powered nanomotors to fight bladder cancer
IBEC researcher Joan Montero authors a paper in Nature Communications which uncovers a key adaptation that melanoma cancer cells use to evade current therapies. This finding might allow physicians to use better drug combinations to improve patient outcomes in the future.
Despite significant advances in cancer diagnosis and treatment, most targeted cancer therapies fail to achieve complete tumor regressions or durable remission. Understanding why these treatments are not always efficient has remained a main challenge for researchers and physicians. Now, Joan Montero from the IBEC and colleagues at Dana-Farber Cancer Institute/Harvard Medical School in USA report in Nature Communications a mechanism that uncovers why some therapies fail to treat melanoma.